Slide 1: Conference Call Nine-month 2018 Results
Conference Call Nine-month 2018 Results Joachim Kreuzburg (CEO), Rainer Lehmann (CFO) October 23, 2018
Slide 2: Disclaimer
Disclaimer This presentation contains statements concerning the future performance of the Sartorius Group and the Sartorius Stedim Biotech Group. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarante
Slide 3: Agenda
Agenda Sartorius Group 9M 2018 Results | FY 2018 Guidance Sartorius Stedim Biotech Group 9M 2018 Results | FY 2018 Guidance Questions & Answers
Slide 4: 9M 2018 Highlights
9M 2018 Highlights Double-digit growth in sales, order intake and earnings Dynamic profitable growth in Bioprocess Solutions; strong order intake Weakening European economy affects Lab Products & Services’ development FY 2018 Group guidance confirmed; division guidance adjusted 4
Slide 5: Strong top-line growth; earnings margin enhanced
Strong top-line growth; earnings margin enhanced Sartorius Group in millions of € unless otherwise specified 9M 20171) 9M 2018 in % in % cc 2) Sales revenue 1,040.4 1,153.7 +10.9 +13.4 Order intake 1,096.4 1,215.2 +10.8 +13.3 Underlying EBITDA3) 255.8 294.2 +15.0 Underlying EBITDA3) margin in % 24.6
Slide 6: Growth in all regions; the Americas record strongest increase
Growth in all regions; the Americas record strongest increase Americas EMEA Asia|Pacific Sales by Region € in millions € in millions € in millions in % 484.1 387.9 448.9 EMEA ~ 42% 335.1 281.7 256.5 Americas ~ 34% ~ €1,153.7m Asia|Pacific ~ 24% 9M 17 9M 18 9M 17 9M 18 9M 17 9M 18 +20.1 % +8.6 % +13.
Slide 7: BPS: Dynamic development against moderate comps
BPS: Dynamic development against moderate comps Order Intake Sales Revenue Underlying EBITDA & Margin € in millions € in millions € in millions +15.0% cc +14.8% cc +16.5% +12.5% +12.2% 901.8 802.0 843.0 239.1 751.1 205.3 28.4% 27.3% 9M 17 9M 18 9M 17 9M 18 9M 17 9M 18 Continuing double-digit growt
Slide 8: LPS: Softer economic environment weighs on growth
LPS: Softer economic environment weighs on growth Order Intake Sales Revenue Underlying EBITDA & Margin € in millions € in millions € in millions +8.7% cc +9.7% cc +9.0% +6.4% +7.4% 294.4 313.4 310.7 55.0 289.3 50.5 17.5% 17.7% 9M 17 9M 18 9M 17 9M 18 9M 17 9M 18 Sales and order growth below expec
Slide 9: Cash flow enhanced by higher earnings
Cash flow enhanced by higher earnings Sartorius Group € in millions unless otherwise specified 9M 20171) 9M 2018 in % Net operating cash flow enhanced by higher earnings Underlying EBITDA 255.8 294.2 +15.0 Net investing cash flow in Extraordinary items -24.3 -19.1 +21.5 previous year primarily r
Slide 10: Key financial indicators remain at robust levels
Key financial indicators remain at robust levels Key Financial Indicators Net Debt and Net Debt to Underlying EBITDA Sartorius Group Dec. 31, 2017 Sep. 30, 2018 1000 3.0 Equity ratio in % 35.1 35.6 800 2.4 600 1.8 Net debt in millions of € 895.5 940.5 400 1.2 Net debt | underlying EBITDA 2.5 2.4 200
Slide 11: Outlook confirmed for Group, adjusted for divisions
Outlook confirmed for Group, adjusted for divisions FY 2018 Guidance1) Previous New Sales revenue Underlying Sales revenue Underlying growth EBITDA margin growth EBITDA margin ~ +0.5pp Sartorius Group ~ 12% - 15% ~ 12% - 15% ~ +0.5pp vs. FY17: 25.1% ~ +0.5pp Upper range Bioprocess Solutions ~ 12% -
Slide 12: Agenda
Agenda Sartorius Group 9M 2018 Results | FY 2018 Guidance Sartorius Stedim Biotech Group 9M 2018 Results | FY 2018 Guidance Questions & Answers
Slide 13: Dynamic profitable growth against moderate comps
Dynamic profitable growth against moderate comps Sartorius Stedim Biotech Group in millions of € unless otherwise specified 9M 20171) 9M 2018 in % in % cc 2) Sales revenue 804.7 896.1 +11.4 +13.8 Order intake 853.0 955.6 +12.0 +14.5 Underlying EBITDA3) 214.5 251.4 +17.2 Underlying EBITDA3) margin in
Slide 14: Growth in all regions, the Americas with highest momentum
Growth in all regions, the Americas with highest momentum Americas EMEA Asia|Pacific Sales by Regions in € millions in € millions in € millions in % 376.5 315.8 344.2 272.6 EMEA ~ 42% 187.9 203.8 Americas ~ 35% ~ €896.1m 9M 17 9M 18 9M 17 9M 18 9M 17 9M 18 +20.3% +9.8% +11.9% Asia|Pacific ~ 23% Acc.
Slide 15: Significant increase in operating cash flow
Significant increase in operating cash flow Sartorius Stedim Biotech Group € in millions unless otherwise specified 9M 20171) 9M 2018 in % Net operating cash flow driven by higher earnings Underlying EBITDA 214.5 251.4 +17.2 Net investing cash flow reflects Extraordinary items -11.9 -8.5 +28.4 e
Slide 16: Financial position remains strong
Financial position remains strong Key Financial Indicators Net Debt and Net Debt to Underlying EBITDA Sartorius Stedim Biotech Dec. 31, 2017 Sep. 30, 2018 180 1.8 Equity ratio in % 62.6 61.6 150 1.5 120 1.2 Net debt in millions of € 127.1 137.9 90 0.9 60 0.6 Net debt | underlying EBITDA 0.4 0.4 30 0
Slide 17: Outlook for 2018 confirmed and specified
Outlook for 2018 confirmed and specified FY 2018 Guidance1) Previous New Upper range Sales revenue growth ~ 11% - 14% ~ 11% - 14% ~28.0% Underlying EBITDA margin ~28.0% vs. FY17: 27.3% CAPEX ratio ~ 15% ~ 15% 1) In constant currencies Growth guidance includes non-organic contribution by recent acq
Slide 18: “EE: sartorius
“EE: sartorius OaA
Slide 19: Thank you very much for your attention
Thank you very much for your attention